Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355082 · ClinicalTrials.gov registry record · Phase 3
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
A Phase 3 study of Epilepsy, Partial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT00355082 is a Phase 3 study of Epilepsy, Partial that has completed, run by GlaxoSmithKline. The registered enrollment target is 226 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT00355082, a Phase 3 study of Epilepsy, Partial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
Conditions Studied
Interventions
- DRUG lamotrigine, 300 mg/day
- DRUG lamotrigine, 250 mg/day
Study Locations (20)
Arizona
- GSK Investigational Site - Litchfield Park
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
- GSK Investigational Site - Tucson
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Pasadena
- GSK Investigational Site - Santa Ana
- GSK Investigational Site - Santa Monica
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Loxahatchee Groves
- GSK Investigational Site - Sunrise
- GSK Investigational Site - Tampa
Connecticut
- GSK Investigational Site - Danbury
- GSK Investigational Site - Fairfield
Alabama
- GSK Investigational Site - Alabaster
Arkansas
- GSK Investigational Site - Fayetteville
Delaware
- GSK Investigational Site - Newark
Georgia
- GSK Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355082
The ClinicalTrials.gov registry entry for NCT00355082 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy, Partial appearing as the primary indexed condition, and to 2 interventions - of which lamotrigine, 300 mg/day is the first listed.
NCT00355082 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00355082 about?
NCT00355082 is a clinical study titled "Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy". This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
What is the current status of trial NCT00355082?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2006-05. Estimated completion is 2008-11.
What conditions does trial NCT00355082 study?
This clinical trial studies the following conditions: Epilepsy, Partial.
What interventions are being tested in trial NCT00355082?
The interventions under investigation include: lamotrigine, 300 mg/day (DRUG), lamotrigine, 250 mg/day (DRUG).
Who is sponsoring clinical trial NCT00355082?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00355082 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.